165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
Rupert Bartsch(Universitätszahnklinik Wien), Matthias Preusser(Medical University of Vienna), Thorsten Fuereder(Medical University of Vienna), Rainer Puhr(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Anna S. Berghoff(Medical University of Vienna), Heidrun Forstner(Medical University of Vienna), Julia Furtner(Medical University of Vienna), C Singer(Medical University of Vienna), Christoph Minichsdorfer(Medical University of Vienna), Angelika M. Starzer(Medical University of Vienna), Elisabeth Bergen(Medical University of Vienna), S. Roider-Schur, Maximilian Marhold(Medical University of Vienna), Georg Widhalm(Medical University of Vienna), Beate Rottenmanner(Medical University of Vienna), Aysegül Ilhan‐Mutlu(Medical University of Vienna), A. Weltermann, Karin Dieckmann(University of Vienna)
Cited by 17
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
|Annals of Oncology|2017|634